title: Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
abstract: There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.
authors.affiliation: Institute for Science, Ethics and Innovation, School of Law, Williamson Building, University of Manchester, Oxford Road, Manchester, UK. catherine.rhodes-2@manchester.ac.uk
authors.forename: Catherine
authors.initials: C
authors.lastname: Rhodes
authors.forename: John
authors.initials: J
authors.lastname: Harris
authors.forename: John
authors.initials: J
authors.lastname: Sulston
authors.forename: Catherine
authors.initials: C
authors.lastname: Spanswick
mesh_terms: D000047:Academies and Institutes; D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D017277:Drug Approval; D004345:Drug Industry / Q000941:ethics; D017408:Guidelines as Topic; D006801:Humans; D007880:Legislation, Drug; D011788:Quality of Life; D000069579:Ranibizumab; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000191:economics*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000069579:Ranibizumab